Testing a key lymph node in patients with the most dangerous form of skin cancer is the best approach to determine if the cancer has spread, new late-stage clinical research indicates. The test could ...

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...

Please provide your email address to receive an email when new articles are posted on . Up to 88% of sentinel lymph node biopsies (SNLB) return with a negative result. The DecisionDx-Melanoma test, ...

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...

TAMPA, Fla. (Oct. 22, 2025) — A large multicenter clinical trial published in JAMA Surgery shows that a gene expression profile–based test can reliably identify melanoma patients who have a low risk ...

ROCHESTER, Minn. — A genomic test co-developed by Mayo Clinic and SkylineDx can identify whether people with melanoma are at low or high risk for cancer in their lymph nodes — a finding that could ...

Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from its prospective ...

Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study March 23, 2026 4:30 ...

March 15 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the ...